Literature DB >> 17485007

Cardiovascular outcome in relation to progression to hypertension in the Copenhagen MONICA cohort.

Tine Willum Hansen1, Jan A Staessen, Haifeng Zhang, Christian Torp-Pedersen, Susanne Rasmussen, Lutgarde Thijs, Hans Ibsen, Jørgen Jeppesen.   

Abstract

BACKGROUND: Previous studies of the risk associated with high-normal blood pressure (BP) determined BP category in a cross-sectional fashion.
METHODS: In 1982-1984, we measured BP in a random sample of 2357 Danes without previous cardiovascular complications, aged 30 to 60 years. We determined progression from optimal (<120/80 mm Hg), normal (120 to 129/80 to 84 mm Hg), and high-normal (130 to 139/85 to 89 mm Hg) BP to hypertension (>or=140/90 mm Hg or start of antihypertensive treatment) by follow-up until 1993-1994. We studied the prognostic significance of progression by subsequent follow-up until 2003.
RESULTS: During 10.9 years (median), the crude progression rates to hypertension from optimal, normal, and high-normal BP were 10.4%, 37.3%, and 58.1%, respectively. During an additional 9.4 years (median), 218 first cardiovascular end points (cardiovascular death, nonfatal stroke, and nonfatal coronary heart disease) occurred. With sustained optimal or normal BP as reference, the multivariate-adjusted hazard ratios were similar (P > .60) for progression to high-normal BP (1.57; 95% confidence interval [CI], 1.06-2.33), for progression to hypertension (1.64; 95% CI, 1.19-2.26), and for sustained high-normal BP or hypertension (1.78; 95% CI, 1.39-2.29). The absolute 10-year cardiovascular risks were 5.1% for optimal or normal BP without progression, 11.1% and 13.9% for progression to high-normal BP or hypertension, respectively, and 18.7% for sustained high-normal BP or hypertension.
CONCLUSIONS: Progressing from optimal or normal BP to high-normal BP or hypertension carries nearly the same risk as sustained high-normal BP or hypertension.

Entities:  

Mesh:

Year:  2007        PMID: 17485007     DOI: 10.1016/j.amjhyper.2006.12.005

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

Review 1.  Arginase and vascular aging.

Authors:  Lakshmi Santhanam; David W Christianson; Daniel Nyhan; Dan E Berkowitz
Journal:  J Appl Physiol (1985)       Date:  2008-08-21

Review 2.  Should Pre-hypertension Be Treated?

Authors:  Hiroshi Kanegae; Takamitsu Oikawa; Kazuomi Kario
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 3.  Out-of-office blood pressure improves risk stratification in normotension and prehypertension people.

Authors:  Kei Asayama; Jana Brguljan-Hitij; Yutaka Imai
Journal:  Curr Hypertens Rep       Date:  2014-10       Impact factor: 5.369

4.  Visceral adiposity index (VAI), a powerful predictor of incident hypertension in prehypertensives.

Authors:  Zhipeng Zhang; Di Shi; Qiang Zhang; Si Wang; Kai Liu; Qingtao Meng; Xiaoping Chen
Journal:  Intern Emerg Med       Date:  2018-03-22       Impact factor: 3.397

5.  Microalbuminuria in untreated prehypertension and hypertension without diabetes.

Authors:  Erhan Tenekecioglu; Mustafa Yilmaz; Osman Can Yontar; Kemal Karaagac; Fahriye Vatansever Agca; Ahmet Tutuncu; Mustafa Kuzeytemiz; Adem Bekler; Muhammed Senturk; Ufuk Aydin; Serafettin Demir
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 6.  Treating prehypertension: a review of the evidence.

Authors:  Norman M Kaplan
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

Review 7.  Prehypertension: epidemiology, consequences and treatment.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Nat Rev Nephrol       Date:  2009-11-17       Impact factor: 28.314

8.  The prevalence of pre-hypertension and hypertension in an Iranian urban population.

Authors:  Ahmad Khosravi; Mohammad Hassan Emamian; Mohammad Shariati; Hassan Hashemi; Akbar Fotouhi
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-11-23

9.  Developing and validating a new precise risk-prediction model for new-onset hypertension: The Jichi Genki hypertension prediction model (JG model).

Authors:  Hiroshi Kanegae; Takamitsu Oikawa; Kenji Suzuki; Yukie Okawara; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-31       Impact factor: 3.738

10.  Which blood pressure measurement, systolic or diastolic, better predicts future hypertension in normotensive young adults?

Authors:  Hiroshi Kanegae; Takamitsu Oikawa; Yukie Okawara; Satoshi Hoshide; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-04-26       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.